– USA, MA – Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company today announced the appointment of Dr. Carsten Brunn (Ph.D.) to its board of directors, bringing more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe.
“I am thrilled to welcome Carsten to the Surface Oncology board. Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we advance our mission of bringing important new IO therapies to patients in need,” said CEO, Dr. Rob Ross.
About Dr. Carsten Brunn
Dr. Carsten Brunn is president and CEO at Selecta Biosciences (Nasdaq: SELB), a clinical-stage precision immune tolerance platform company. Before joining Selecta, he was president of pharmaceuticals for the Americas region at Bayer, and before that, he served as president of Bayer Pharmaceuticals in Japan. Dr. Brunn previously served on the board of directors of the Biotechnology Innovation Organization, and he was chairman of the European Federation of Pharmaceutical Industries and Associations Japan. Over his extensive career, Dr. Brunn has held leadership positions at Eli Lilly, Novartis, Basilea, and Bausch and Lomb.
“Surface has a compelling pipeline of novel antibodies which hold the potential to improve the lives of people confronting a variety of cancers,” said Dr. Brunn. “I am tremendously excited to be joining the Surface board, and I look forward to lending my skills and experience to support the management team in their important work.”
He graduated from the University of Freiburg in Germany with an M.S. in pharmaceutical sciences, and he earned his Ph.D. in chemistry from the University of Hamburg, Germany. He also studied at the University of Washington and completed his executive education at London Business School.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational, cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
For more information: https://www.surfaceoncology.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.